Tenet raises EBITDA outlook as USPI and high-acuity care lead growth

Transcript intelligence

What changed

The company raised full-year 2026 adjusted EBITDA guidance to $5.05-$5.2 billion. Q3 also highlighted 9% USPI EBITDA growth, 3.2% hospital admission growth, $1.1 billion of quarterly free cash flow and $147 million of Conifer transition revenue timing, with $50 million of related EBITDA. Management said $450 million of Conifer transition EBITDA expected in 2026 will not recur in 2027.

Guidance delta

Management raised full-year 2026 adjusted EBITDA guidance to $5.05-$5.2 billion, while noting that $450 million of Conifer transition EBITDA is not expected to recur in 2027.

Key takeaways

• USPI adjusted EBITDA grew 9%, with same-store joint-replacement growth of 12.8% and four new de novo centers opened.
• Hospital adjusted admissions grew 3.2%, with continued margin expansion tied to the high-acuity strategy.
• Free cash flow of $1.1 billion in Q3 supported $1.6 billion of share repurchases year to date and a deleveraged balance sheet.
• Management expects 2027 EBITDA growth after normalizing for non-recurring Conifer transition items.
• Payer mix, exchange enrollment, Medicaid policy and regulatory changes remain material uncertainties.

Management priorities

• Expand USPI through acquisitions and de novo centers.
• Invest in high-acuity hospital services and transfer programs.
• Use AI and analytics to improve OR scheduling and case utilization.
• Deploy free cash flow toward repurchases and potential debt refinancing.
• Develop 2027 guidance after further business planning in Q4.